Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Zhejiang Huahai Pharmaceutical Co., Ltd., commonly known as Huahai, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in China. Established in 1989, the company has grown significantly, with major operational regions spanning across Asia, Europe, and North America.
Huahai focuses on the development and production of a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. Its commitment to quality and innovation sets it apart in a competitive market. The company has achieved notable milestones, including certifications from various international regulatory bodies, which underscore its dedication to maintaining high standards.
With a strong market position, Huahai continues to expand its portfolio, contributing to global healthcare solutions while ensuring the delivery of safe and effective medications.
-14 vs industry average
Zhejiang Huahai’s score of 28 is lower than 40% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Zhejiang Huahai yet.
Zhejiang Huahai, a Pharmaceutical Preparation Manufacturing company based in China, has not publicly reported its direct (Scope 1), indirect (Scope 2), or value chain (Scope 3) greenhouse gas emissions.
However, Zhejiang Huahai Pharmaceutical Co., Ltd. has established near-term science-based targets. The company is committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, using 2023 as a base year. Additionally, Zhejiang Huahai Pharmaceutical Co., Ltd. aims to reduce Scope 3 GHG emissions by 51.6% per million CNY value added by 2030, from a 2022 base year. These targets are consistent with reductions required to limit global warming to 1.5°C.
2030
51.6% reduction in scope 3 total
Zhejiang Huahai Pharmaceutical Co., Ltd also commits to reduce scope 3 GHG emissions 51.6% per million CNY value added by 2030 from a 2022 b…
2030
42% reduction in Scope 1
Zhejiang Huahai Pharmaceutical Co., Ltd commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2023 base year.
2030
42% reduction in Scope 2
Zhejiang Huahai Pharmaceutical Co., Ltd commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2023 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Zhejiang Huahai’s sustainability data and climate commitments
Data year: 2020
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more